Paying users zone. Data is hidden behind: .
Get 1-month access to Intuitive Surgical Inc. for $17.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Intuitive Surgical Inc. pages available today for free:
Common Stock Valuation Ratios (Price Multiples)
Quarterly Data
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Intuitive Surgical Inc., historical price multiples (quarterly data)
Based on: 10-K (filing date: 2021-02-10), 10-Q (filing date: 2020-10-19), 10-Q (filing date: 2020-07-23), 10-Q (filing date: 2020-04-17), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-10-18), 10-Q (filing date: 2019-07-22), 10-Q (filing date: 2019-04-19), 10-K (filing date: 2019-02-04), 10-Q (filing date: 2018-10-22), 10-Q (filing date: 2018-07-20), 10-Q (filing date: 2018-04-18), 10-K (filing date: 2018-02-02), 10-Q (filing date: 2017-10-20), 10-Q (filing date: 2017-07-21), 10-Q (filing date: 2017-04-19), 10-K (filing date: 2017-02-06), 10-Q (filing date: 2016-10-19), 10-Q (filing date: 2016-07-20), 10-Q (filing date: 2016-04-19).
Valuation ratio | Description | The company |
---|---|---|
P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Intuitive Surgical Inc.’s P/E ratio increased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Intuitive Surgical Inc.’s P/OP ratio increased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Intuitive Surgical Inc.’s P/S ratio increased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. | Intuitive Surgical Inc.’s P/BV ratio increased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
Price to Earnings (P/E)
Intuitive Surgical Inc., historical P/E calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | ||||||||||||||||||||||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||
Net income attributable to Intuitive Surgical, Inc. (in thousands) | ||||||||||||||||||||||||||
Earnings per share (EPS)2 | ||||||||||||||||||||||||||
Share price1, 3 | ||||||||||||||||||||||||||
Valuation Ratio | ||||||||||||||||||||||||||
P/E ratio4 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
P/E Ratio, Competitors5 | ||||||||||||||||||||||||||
Becton, Dickinson & Co. | ||||||||||||||||||||||||||
Boston Scientific Corp. | ||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||
Edwards Lifesciences Corp. | ||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||
Stryker Corp. | ||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-K (filing date: 2021-02-10), 10-Q (filing date: 2020-10-19), 10-Q (filing date: 2020-07-23), 10-Q (filing date: 2020-04-17), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-10-18), 10-Q (filing date: 2019-07-22), 10-Q (filing date: 2019-04-19), 10-K (filing date: 2019-02-04), 10-Q (filing date: 2018-10-22), 10-Q (filing date: 2018-07-20), 10-Q (filing date: 2018-04-18), 10-K (filing date: 2018-02-02), 10-Q (filing date: 2017-10-20), 10-Q (filing date: 2017-07-21), 10-Q (filing date: 2017-04-19), 10-K (filing date: 2017-02-06), 10-Q (filing date: 2016-10-19), 10-Q (filing date: 2016-07-20), 10-Q (filing date: 2016-04-19).
1 Data adjusted for splits and stock dividends.
2 Q4 2020 Calculation
EPS
= (Net income attributable to Intuitive Surgical, Inc.Q4 2020
+ Net income attributable to Intuitive Surgical, Inc.Q3 2020
+ Net income attributable to Intuitive Surgical, Inc.Q2 2020
+ Net income attributable to Intuitive Surgical, Inc.Q1 2020)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Intuitive Surgical Inc.’s Quarterly or Annual Report.
4 Q4 2020 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Intuitive Surgical Inc.’s P/E ratio increased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
Price to Operating Profit (P/OP)
Intuitive Surgical Inc., historical P/OP calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | ||||||||||||||||||||||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||
Income from operations (in thousands) | ||||||||||||||||||||||||||
Operating profit per share2 | ||||||||||||||||||||||||||
Share price1, 3 | ||||||||||||||||||||||||||
Valuation Ratio | ||||||||||||||||||||||||||
P/OP ratio4 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
P/OP Ratio, Competitors5 | ||||||||||||||||||||||||||
Becton, Dickinson & Co. | ||||||||||||||||||||||||||
Boston Scientific Corp. | ||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||
Edwards Lifesciences Corp. | ||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||
Stryker Corp. | ||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-K (filing date: 2021-02-10), 10-Q (filing date: 2020-10-19), 10-Q (filing date: 2020-07-23), 10-Q (filing date: 2020-04-17), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-10-18), 10-Q (filing date: 2019-07-22), 10-Q (filing date: 2019-04-19), 10-K (filing date: 2019-02-04), 10-Q (filing date: 2018-10-22), 10-Q (filing date: 2018-07-20), 10-Q (filing date: 2018-04-18), 10-K (filing date: 2018-02-02), 10-Q (filing date: 2017-10-20), 10-Q (filing date: 2017-07-21), 10-Q (filing date: 2017-04-19), 10-K (filing date: 2017-02-06), 10-Q (filing date: 2016-10-19), 10-Q (filing date: 2016-07-20), 10-Q (filing date: 2016-04-19).
1 Data adjusted for splits and stock dividends.
2 Q4 2020 Calculation
Operating profit per share
= (Income from operationsQ4 2020
+ Income from operationsQ3 2020
+ Income from operationsQ2 2020
+ Income from operationsQ1 2020)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Intuitive Surgical Inc.’s Quarterly or Annual Report.
4 Q4 2020 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Intuitive Surgical Inc.’s P/OP ratio increased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
Price to Sales (P/S)
Intuitive Surgical Inc., historical P/S calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | ||||||||||||||||||||||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||
Revenue (in thousands) | ||||||||||||||||||||||||||
Sales per share2 | ||||||||||||||||||||||||||
Share price1, 3 | ||||||||||||||||||||||||||
Valuation Ratio | ||||||||||||||||||||||||||
P/S ratio4 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
P/S Ratio, Competitors5 | ||||||||||||||||||||||||||
Becton, Dickinson & Co. | ||||||||||||||||||||||||||
Boston Scientific Corp. | ||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||
Edwards Lifesciences Corp. | ||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||
Stryker Corp. | ||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-K (filing date: 2021-02-10), 10-Q (filing date: 2020-10-19), 10-Q (filing date: 2020-07-23), 10-Q (filing date: 2020-04-17), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-10-18), 10-Q (filing date: 2019-07-22), 10-Q (filing date: 2019-04-19), 10-K (filing date: 2019-02-04), 10-Q (filing date: 2018-10-22), 10-Q (filing date: 2018-07-20), 10-Q (filing date: 2018-04-18), 10-K (filing date: 2018-02-02), 10-Q (filing date: 2017-10-20), 10-Q (filing date: 2017-07-21), 10-Q (filing date: 2017-04-19), 10-K (filing date: 2017-02-06), 10-Q (filing date: 2016-10-19), 10-Q (filing date: 2016-07-20), 10-Q (filing date: 2016-04-19).
1 Data adjusted for splits and stock dividends.
2 Q4 2020 Calculation
Sales per share
= (RevenueQ4 2020
+ RevenueQ3 2020
+ RevenueQ2 2020
+ RevenueQ1 2020)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Intuitive Surgical Inc.’s Quarterly or Annual Report.
4 Q4 2020 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Intuitive Surgical Inc.’s P/S ratio increased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
Price to Book Value (P/BV)
Intuitive Surgical Inc., historical P/BV calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | ||||||||||||||||||||||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||
Total Intuitive Surgical, Inc. stockholders’ equity (in thousands) | ||||||||||||||||||||||||||
Book value per share (BVPS)2 | ||||||||||||||||||||||||||
Share price1, 3 | ||||||||||||||||||||||||||
Valuation Ratio | ||||||||||||||||||||||||||
P/BV ratio4 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
P/BV Ratio, Competitors5 | ||||||||||||||||||||||||||
Becton, Dickinson & Co. | ||||||||||||||||||||||||||
Boston Scientific Corp. | ||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||
Edwards Lifesciences Corp. | ||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||
Stryker Corp. | ||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-K (filing date: 2021-02-10), 10-Q (filing date: 2020-10-19), 10-Q (filing date: 2020-07-23), 10-Q (filing date: 2020-04-17), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-10-18), 10-Q (filing date: 2019-07-22), 10-Q (filing date: 2019-04-19), 10-K (filing date: 2019-02-04), 10-Q (filing date: 2018-10-22), 10-Q (filing date: 2018-07-20), 10-Q (filing date: 2018-04-18), 10-K (filing date: 2018-02-02), 10-Q (filing date: 2017-10-20), 10-Q (filing date: 2017-07-21), 10-Q (filing date: 2017-04-19), 10-K (filing date: 2017-02-06), 10-Q (filing date: 2016-10-19), 10-Q (filing date: 2016-07-20), 10-Q (filing date: 2016-04-19).
1 Data adjusted for splits and stock dividends.
2 Q4 2020 Calculation
BVPS = Total Intuitive Surgical, Inc. stockholders’ equity ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Intuitive Surgical Inc.’s Quarterly or Annual Report.
4 Q4 2020 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. | Intuitive Surgical Inc.’s P/BV ratio increased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |